EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 28th, 2022 • Tilray Brands, Inc. • Medicinal chemicals & botanical products • Delaware
Contract Type FiledJuly 28th, 2022 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement') is effective as of the 26th day of July, 2021 (the “Effective Date”) by and between Tilray, Inc., a Delaware corporation (the "Company") and Mitchell Gendel (the "Executive").
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 7th, 2021 • Tilray, Inc. • Medicinal chemicals & botanical products • Delaware
Contract Type FiledOctober 7th, 2021 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement') is effective as of the 26th day of July, 2021 (the “Effective Date”) by and between Tilray, Inc., a Delaware corporation (the "Company") and Denise Faltischek (the "Executive").
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 7th, 2021 • Tilray, Inc. • Medicinal chemicals & botanical products • Ontario
Contract Type FiledOctober 7th, 2021 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement') is entered into this 26th day of July, 2021 (the “Effective Date”) by and between Tilray, Inc., a Delaware corporation (the "Company") and Carl Merton (the "Executive").
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 7th, 2021 • Tilray, Inc. • Medicinal chemicals & botanical products • Delaware
Contract Type FiledOctober 7th, 2021 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement') is effective as of the 26th day of July, 2021 (the “Effective Date”) by and between Tilray, Inc., a Delaware corporation (the "Company") and James Meiers (the "Executive").
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 6th, 2020 • Immunomedics Inc • In vitro & in vivo diagnostic substances • New Jersey
Contract Type FiledMay 6th, 2020 Company Industry JurisdictionTHIS EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement') is entered into this 16th day of April, 2020 by and between Immunomedics, Inc., a Delaware corporation having its principal offices in Morris Plains, New Jersey (the "Company") and Harout Semerjian (the "Executive").